Bio-Path Holdings 宣布一项新的肥胖治疗计划并完成难治性白血病试验的入组。 Bio-Path Holdings announces a new obesity therapeutic program and enrollment completion for a refractory leukemia trial.

Bio-Path Holdings Inc. 在宣布一项旨在治疗肥胖和代谢疾病的 BP1001-A 新治疗计划后，股价大幅上涨，这标志着其 DNAbilize 技术的第一个非癌症应用。 Bio-Path Holdings Inc. saw a significant stock price increase following its announcement of a new therapeutic program for BP1001-A, aimed at treating obesity and metabolic diseases, marking its first non-cancer application of DNAbilize technology. 预计临床研究将在Q4 2024年开始。 Preclinical studies are expected to begin in Q4 2024. 此外，该公司还完成了 BP1002 试验的第三个给药队列的入组，该试验针对难治性急性髓系白血病患者，包括对维奈托克耐药的患者。 Additionally, the company completed enrollment for the third dosing cohort in a trial for BP1002, targeting refractory acute myeloid leukemia patients, including those resistant to venetoclax.